Sign in with Google
bearish
Shanghai Henlius (复宏汉霖) IPO: Thoughts on Price Range, Cornerstone, Valuation Trap
702 Views11 Sep 2019 06:19
Shanghai Henlius, a biotech subsidiary of Fosun Pharma, launched book building today to raise up to USD 477 million.
In our previous insights...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 3-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Goldlion Holdings (533 HK): An Unexpected HK Arbageddon
- [Japan M&A] Son of Chairman/55%Owner Taking Imagica (6879) Private at 10x FCF, 4+x EBITDA. CHEAP.
- Curator's Cut: "Bubble" Tea, Japan M&A 🍿and TSMC from Different Lenses
- [Japan M&A] Bloomberg Reports Bain MBO on Nissin (9066) May Come Monday - The Implied Price Is Light
- Sinarmas Land (SML SP): Potential Outcomes as IFA Says NOT Fair but Reasonable
Top Unpaywalled Insights
More »- Curator's Cut: "Bubble" Tea, Japan M&A 🍿and TSMC from Different Lenses
- The Coming Global Trade Re-Ordering
- The Polycrisis Era (2025–2028): Navigating a World of Overlapping Disruptions
- Our AI-Powered Accounting Risk Trading Strategy Beat the S&P 500 by 2.5x
- India-UK Free Trade Agreement: A New Era for India's Textile Industry
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Shanghai Henlius (复宏汉霖) IPO: Take-Aways from Peer PD-1 Sales in China18 Sep 2019
- ECM Weekly (14 Sep 2019) - Budweiser APAC, ESR Cayman, Henlius, AllHome, Topsports14 Sep 2019
- Shanghai Henlius (复宏汉霖) IPO: Newsflow on HLX10 Clinical Trial and ASEAN Commercialization13 Sep 2019
- Shanghai Henlius (复宏汉霖) IPO: Thoughts on Price Range, Cornerstone, Valuation Trap11 Sep 2019
- Shanghai Henlius (复宏汉霖) IPO: Thoughts on Valuation22 Aug 2019
- Shanghai Henlius (复宏汉霖) IPO: What's New in the Re-Filed Prospectus?17 Jul 2019
x